Refine by
Therapeutic Potential Equipment & Supplies
125 equipment items found
by:Starpharma Holdings Limited based inMelbourne, AUSTRALIA
DEP® docetaxel is an enhanced version of docetaxel (Taxotere®) – widely used for breast, lung & prostate cancer. Docetaxel (Taxotere®) is a commonly used chemotherapy agent despite having multiple US FDA “Black Box” warnings. DEP® docetaxel is a detergent free, aqueous formulation of docetaxel. ...
by:Neurona Therapeutics based inSouth San Francisco, CALIFORNIA (USA)
Chronic Disorders of the Nervous System are Prime Indications for Regenerative Medicine. Neurona is a clinical-stage biotherapeutics company developing regenerative cell therapies that permanently integrate into neural circuits, replace affected cells, and rebalance dysregulated electrical activity to repair the nervous system. Neural cell therapies have the potential to achieve long-lasting ...
Manufactured by:Boston Pharmaceuticals based inCambridge, MASSACHUSETTS (USA)
BOS-704 is a ghrelin O-acyl transferase inhibitor with therapeutic potential for multiple ...
Manufactured by:Boston Pharmaceuticals based inCambridge, MASSACHUSETTS (USA)
BOS-857 is a first-in-class, inhaled, small molecule furin inhibitor with therapeutic potential in pulmonary diseases, including cystic fibrosis (CF), vascular diseases, and infectious ...
Manufactured by:Altucell, Inc. based inNew York, NEW YORK (USA)
Encapsulated cell therapy is an emerging area of biopharmaceutical research that aims to unleash the therapeutic potential of cells to treat serious diseases without the need for immunosuppression. Altucell has developed patented, proprietary engineered cells that are combined with a patented encapsulation technology to create effective ...
by:Orion Biotechnology Canada, Ltd. based inOttawa, SWITZERLAND
Orion’s platform and science unlocks the therapeutic potential of GPCR targets across a broad range of medical needs. Our approach allows us to focus our discovery and development efforts across peptide and protein GPCR subfamilies, generating a diversified pipeline of potential first-in-class/best-in-class antagonist and ...
by:Vir Biotechnology, Inc. based inSan Francisco, CALIFORNIA (USA)
We have established a robust method for capitalizing on unusually successful immune responses naturally occurring in people who are protected from, or have recovered from, infectious diseases. We identify rare antibodies from survivors that have the potential to treat and prevent rapidly evolving and/or previously untreatable pathogens via direct pathogen neutralization and ...
Manufactured by:Boston Pharmaceuticals based inCambridge, MASSACHUSETTS (USA)
BOS-981 is a first-in-class, small molecule furin inhibitor with therapeutic potential in pulmonary diseases, including cystic fibrosis (CF), vascular diseases, and infectious ...
Manufactured by:Kiadis Pharma NV based inAmsterdam, NETHERLANDS
Accessing a new repertoire of targets. Two classes of molecule with therapeutic potential that are not currently addressed by antibody drugs are G-protein-coupled receptors and ion channels, largely because they display small epitopes not accessible to traditional antibodies and their sequence is often conserved and thus less likely to be ...
by:Verb Biotics based inBoston, MASSACHUSETTS (USA)
Yso5 is a discovery-stage program leveraging a specific keystone gut bacteria (undisclosed) to potentiate the effects of Immune Checkpoint Blockade (ICB) drugs. The field of cancer therapy has been revolutionized by the use of immunotherapy. The microbiome breakthrough science today paves the way for innovative biotherapies to potentiate the effectiveness of ...
Manufactured by:Inversago Pharma based inMontreal, QUEBEC (CANADA)
Inversago Pharma Inc. is focused on the development of peripherally-acting CB1 receptor (CB1) inverse agonists for the treatment of diabetic nephropathy, NASH, type 1 diabetes and Prader-Willi Syndrome. While previous generation of centrally-acting CB1 inhibitors presented safety concerns, the therapeutic relevance of peripheral CB1 pathway is still strongly supported by ...
Manufactured by:Sangamo Therapeutics based inBrisbane, CALIFORNIA (USA)
Sangamo’s proprietary zinc finger (ZF) platform uniquely confers a number of advantages and has broad therapeutic potential due to its versatility, specificity and clinical utility. Zinc finger technologies are composed of a DNA-binding domain, which binds with precision to any sequence of DNA, and various functional domains (such as nucleases and ...
Manufactured by:Juvena Therapeutics, inc. based inRedwood City, CALIFORNIA (USA)
Secreted proteins are a proven class of biologics with tremendous therapeutic potential, as they regulate tissue repair and regeneration, organ development, and immune response to disease. The characteristics of secreted proteins render them a rich pool of drug candidates for chronic and age-related diseases. Our therapeutic approach is to unlock ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
RLX (PD 139530) is a PI3K/Akt/FoxO3a signaling inhibitor, possessing significant therapeutic potential in experimental colon cancer. RLX can effectively modulate the tumor microenvironment, enhancing the efficacy of cancer immunotherapy. RLX demonstrates the ability to improve the retention time of therapeutic agents within the tumor ...
Manufactured by:Scancell based inOxford, UNITED KINGDOM
Glycosylation is increasingly recognised as a modulator of the malignant phenotype of cancer cells, where the interaction between cells and the tumour micro-environment is altered to facilitate processes such as drug resistance, metastasis and immune evasion. Antibodies recognising tumour-associated glycans could therefore have excellent therapeutic ...
Manufactured by:Kiadis Pharma NV based inAmsterdam, NETHERLANDS
They were first described in the 1970s, but only in the last 15 years has significant progress been made in understanding the complexities and therapeutic potential these cells offer in helping fight cancer and other diseases.1 Today, we know that NK cells not only detect and identify malignant cancer cells, but they also induce cancer cell death4,5 and even ...
Manufactured by:Feldan Therapeutics based inQuebec, QUEBEC (CANADA)
We have designed the Feldan Shuttle, a versatile biotechnology that enables safe and efficient delivery of therapeutic compounds into cells. By giving access to intracellular space, this unique technology is unlocking the potential of therapeutics that target intracellular components and contributes to the development of revolutionary ...
Manufactured by:Regeneron Pharmaceuticals Inc. based inTarrytown, NEW YORK (USA)
This approach overcomes the limitations of traditional platforms by rapidly creating fully human antibodies that tightly bind to therapeutic targets and avoid potential immune responses that may occur in patients receiving antibodies that contain nonhuman (typically mouse) ...
Manufactured by:Celularity Inc. based inFlorham Park, NEW JERSEY (USA)
Celularity’s unique technology realizes the full promise of cell therapies by harnessing the immunomodulatory and regenerative properties of the postpartum ...
Manufactured by:Regeneron Pharmaceuticals Inc. based inTarrytown, NEW YORK (USA)
VelociMab is a group of technologies that allow us to move with unprecedented speed from identification of a therapeutic antibody into clinical studies. VelociMab enables the high-throughput screening of potential therapeutic antibodies and the rapid generation of cell lines for recombinant human antibodies. It allows researchers to go from mouse ...